The average trial participant is an urban male, of European ancestry, and high socioeconomic status. This limits our understanding of how medical products operate in all genders, socioeconomic statuses, races and ethnicities. The exclusion of people in the product design, product development, and product testing phases create products and services that are narrow in reach, unable to fully relate to all users, and unable to stay relevant. Everyone should benefit from innovative technology- and- in fact, these technologies should be tailored to the populations most impacted.
It is critical for more stakeholders to view the entire value chain of product development, considering who:
It is a moral imperative for product developers to understand the innovation value chain. Furthermore, all stakeholders must consider that their continued participation in an inequitable value chain further compounds programs, systems, and norms that perpetuate inequity. We support our clients to increase the number of, and diversity of market segments that are reached by their products, unlocking global participation and access. Because of this, our clients improve their revenues, are more trusted by those they aim to help, and develop programming that serves the underserved.